Cargando…
Circulating miRNA markers show promise as new prognosticators for multiple myeloma
Autores principales: | Rocci, A, Hofmeister, CC, Geyer, S, Stiff, A, Gambella, M, Cascione, L, Guan, J, Benson, DM, Efebera, YA, Talabere, T, Dirisala, V, Omedè, P, Isaia, G, De Luca, L, Rossi, D, Gentili, S, Uccello, G, Consiglio, J, Ria, R, Benevolo, G, Bringhen, S, Callea, V, Weiss, B, Magarotto, V, Alder, H, Byrd, JC, Boccadoro, M, Marcucci, G, Palumbo, A, Pichiorri, F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155011/ https://www.ncbi.nlm.nih.gov/pubmed/24813918 http://dx.doi.org/10.1038/leu.2014.155 |
Ejemplares similares
-
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
por: Pichiorri, Flavia, et al.
Publicado: (2013) -
Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
por: Pichiorri, Flavia, et al.
Publicado: (2017) -
HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
por: Canella, Alessandro, et al.
Publicado: (2015) -
Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
por: Canella, Alessandro, et al.
Publicado: (2023) -
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
por: Saltarella, Ilaria, et al.
Publicado: (2019)